Abstract
Pulmonary arterial hypertension (PAH) is a progressive, debilitating, and potentially fatal disease. Symptoms of PAH are non-specific and may include dyspnea, fatigue, chest discomfort, pre-syncope/syncope, palpitations, lower extremity swelling, non-specific gastro-intestinal symptoms, weight loss, and cyanosis. Pulmonologists are increasingly involved in the care of these patients, whether at the initial presentation and diagnosis, medication titration, or for symptom relief and management of complications. The pulmonologist and intensivist also frequently care for patients that are at an increased risk of developing PAH, such as patients with cirrhosis, hypoxic lung disease, scleroderma, sickle cell disease, and HIV to name a few. An echocardiogram, although often inaccurate in estimating the right-sided heart pressures, is the best screening tool for PAH. A right heart catheterization is the gold standard for diagnosing PAH. Supplemental therapies may include oxygen, diuretics, and anticoagulation. In addition to the limited role of calciumchannel blockers, PAH-specific therapies fall into one of 3 families for now: Phospho-diesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclins. The current estimated 2 year survival of PAH patients now exceeds 90%, compared to a historical median survival of 2-3 years.
Keywords: Pulmonary hypertension, diagnosis, management, Dana Point, ERA, PDE5 inhibitor, prostanoid, Clinical Presentation, Symposium, fatal disease, pulmonary artery, anti-inflammatory molecules, hepatitis C
Current Respiratory Medicine Reviews
Title: Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Volume: 7 Issue: 4
Author(s): Wassim H. Fares, Hubert James Ford and Robert M. Aris
Affiliation:
Keywords: Pulmonary hypertension, diagnosis, management, Dana Point, ERA, PDE5 inhibitor, prostanoid, Clinical Presentation, Symposium, fatal disease, pulmonary artery, anti-inflammatory molecules, hepatitis C
Abstract: Pulmonary arterial hypertension (PAH) is a progressive, debilitating, and potentially fatal disease. Symptoms of PAH are non-specific and may include dyspnea, fatigue, chest discomfort, pre-syncope/syncope, palpitations, lower extremity swelling, non-specific gastro-intestinal symptoms, weight loss, and cyanosis. Pulmonologists are increasingly involved in the care of these patients, whether at the initial presentation and diagnosis, medication titration, or for symptom relief and management of complications. The pulmonologist and intensivist also frequently care for patients that are at an increased risk of developing PAH, such as patients with cirrhosis, hypoxic lung disease, scleroderma, sickle cell disease, and HIV to name a few. An echocardiogram, although often inaccurate in estimating the right-sided heart pressures, is the best screening tool for PAH. A right heart catheterization is the gold standard for diagnosing PAH. Supplemental therapies may include oxygen, diuretics, and anticoagulation. In addition to the limited role of calciumchannel blockers, PAH-specific therapies fall into one of 3 families for now: Phospho-diesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclins. The current estimated 2 year survival of PAH patients now exceeds 90%, compared to a historical median survival of 2-3 years.
Export Options
About this article
Cite this article as:
H. Fares Wassim, James Ford Hubert and M. Aris Robert, Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights, Current Respiratory Medicine Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339811798281197
DOI https://dx.doi.org/10.2174/157339811798281197 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry The Use of the Dahl Rat to Understand the Genetics of Human Hypertension: 35 Years of Data
Current Hypertension Reviews Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Application of MALDI-TOF Mass Spectrometry in Screening and Diagnostic Research
Current Pharmaceutical Design Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology Active Coatings: Examples and Applications
Recent Patents on Mechanical Engineering Therapies Targeting Inflammation After Stent Implantation
Current Vascular Pharmacology Molecular Determinants of Vascular Calcification: A Bench to Bedside View
Current Molecular Medicine Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology